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Abstract
Background: Pancreatic adenocarcinoma is currently the fourth-leading cause of cancer-related death. Up to
60–90% of patients with advanced disease suffer cancer-related pain, severely impacting their quality of life.
Current management involves primarily pharmacotherapy with opioid narcotics and celiac plexus neurolysis;
unfortunately, both approaches offer transient relief and cause undesired side-effects. High intensity focused
ultrasound (HIFU) is a non-invasive thermal ablation technique that has been used to treat pancreatic cancer.
This meta-analysis aims to evaluate the role of HIFU in pain palliation of advanced unresectable pancreatic
adenocarcinoma.
Methods: An electronic search was performed in PubMed Medline database up to the end of July 2016, for
unresectable pancreatic cancer pain palliation with HIFU. Pertinent studies were identified through the
PubMed search engine using the following keywords: HIFU, pancreas, pancreatic cancer, pain and palliation.
Additional studies were included after manual search of the selected bibliographies. Pain palliation results
reported in each study were analyzed using a logit-transformed random-effects model using the inverse
variance method, with the DerSimonian-Laird estimator for τ2, and Cochran’s Q test for heterogeneity among
studies. The I2 was calculated to assess the percentage of the total variability in the different effect size
estimates that can be attributed to heterogeneity among the true effects. A rank correlation test of funnel
plot asymmetry was done to assess possible publication bias.
Results: The meta-analysis includes a total number of 23 studies with 865 patients, 729 with pancreatic cancer. The
population enrolled ranges from 3 patients in the smallest series, up to 61 in the largest study. τ2 (variance among
studies) was 0.195, and I2 (percentage of variation among studies) was 40% (95% CI: 1–64%); the Q test p-value was 0.
026, indicating significant heterogeneity among studies. Among 639 patients treated with HIFU, 567 complained of
pancreatic pain before the treatment and 459 patients experienced partial or complete pain relief after treatment. The
random effects estimate of the proportion of patients with pain reduction was 0.81 (95% CI: 0.76–86).
(Continued on next page)
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Conclusions: HIFU appears to be an effective tool for pain palliation in advanced pancreatic cancer. Studies assessing
treatment in patients with pancreatic adenocarcinoma are limited by factors such as small sample sizes and
heterogeneity in clinical definitions and assessments. Prospective randomized and standardized studies are necessary
to confirm the effectiveness of HIFU in relieving pain, and to evaluate for any potential impact on tumor control and
patient survival.
Keywords: Pancreatic cancer, High intensity focused ultrasound, HIFU, Pain palliation, Pain relief, Non-invasive
treatment, Meta-analysis
Background
Pancreatic cancer incidence is increasing worldwide with
53070 new cases and 41780 deaths estimated in 2016, and
is currently the fourth cause of cancer-related death [1, 2].
It more frequently affects men between 65 and 84 years of
age and occurs predominantly in the Western countries,
where environmental factors may play an important role
in the pathogenesis [3]. Ductal pancreatic adenocarcin-
oma, the most common histology, accounts for 85–90% of
these cancers [4].
Despite advances in diagnostic methods and the develop-
ment of new therapeutic approaches, the prognosis for
pancreatic cancer has remained dismal over the past
40 years [4], with an overall 5-year survival rate of less than
8%, a median survival rate of 6–10 months for unresect-
able, locally advanced disease, and 3 to 6 months for
patients with metastases [5]. The only possibility of cure is
through surgery; however, due to the late appearance of
symptoms, less than 20% of patients present with resect-
able disease at the time of diagnosis [6]. Moreover, mortal-
ity remains high even after surgery due to the high loco-
regional recurrence rate and the tendency for early
metastatic spread [7]. Considering the poor prognosis of
these patients, the principal goals of pancreatic cancer
therapy in advanced disease are to palliate symptoms and
increase the overall survival. Throughout the illness and
during end-of-life care, patients need comprehensive
symptom control. Pain is common in patients with pancre-
atic cancer, and is reported by 60–90% of patients with
advanced disease [8]. It is often described as dull pain,
sometimes with colicky spasms, and is referred to the mid
back or epigastric regions [9]. Gemcitabine-based chemo-
therapy and chemoradiation combinations produce a
limited improvement in survival, but are not very effective
in pain relief and are associated with high toxicity [10].
The current management of pancreatic cancer-related pain
primarily involves pharmacotherapy with opioid narcotics
and celiac plexus neurolysis. Unfortunately, opioid
narcotics often cause undesired side effects ranging from
mild constipation to altered mental status. In addition,
some opioids can have a dysphoric effect that can signifi-
cantly impact the patients’ quality of life [11]. Celiac plexus
neurolysis is performed in patients who have severe
intractable pain that is poorly controlled on opioids;
however, the procedure is invasive, requiring endoscopic
ultrasound or CT-guidance. Initial uncontrolled and retro-
spective case series suggested that partial or complete pain
relief was achieved in 70–90% of patients undergoing
neurolytic celiac plexus blockade (NCPB) [12]; however, a
meta-analysis of five randomized controlled trials of NCPB
demonstrated that the overall benefit was small, with only
a 6% reduction in the mean visual analogue pain score
compared to baseline [13]. Clearly, new methods are
needed to both treat and palliate patients with advanced
pancreatic cancer.
High intensity focused ultrasound (HIFU) is a non-
invasive imaging-guided thermal ablation technique that
uses an extracorporeal transducer to deliver ultrasound
energy to induce an increase of temperature in a sharply
demarcated region. Ultrasound or magnetic resonance
imaging are used to assess the anatomy of the region for
targeting and to provide real time feedback during abla-
tion [14]. HIFU has a dual effect on the target tissue,
inducing thermal and mechanical damage. During the
treatment, the targeted tissue is heated to the 60–80 °C
range within seconds, inducing liquefaction and coagula-
tion necrosis in the targeted region, with the goal of
thermal ablation of the tumor without affecting the
surrounding healthy tissue [14, 15]. The temperature
reached is not high enough to cause an immediate
necrosis of the cells, but it induces first intracellular
denaturation of protein, and thus of the stored pancre-
atic enzymes, followed by cellular degeneration and
necrosis. This “thermal fixation” phenomenon poten-
tially reduces the risk of pancreatitis as a complication
of the procedure [15]. In addition to thermal effects,
there are three mechanical effects associated with high
intensity acoustic energy: cavitation, microstreaming and
radiation force. Cavitation results from the oscillating
motion of gas-filled bubbles (stable cavitation); these
bubbles coalesce and collapse under higher ultrasound
field energy, causing a shock wave confined to the
microenvironment (inertial cavitation) [16, 17]. Micro-
streaming is the consequence of stable cavitation occur-
ring close to fluids, producing shear stress that
transiently damages the cell membrane [18]. Lastly,
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radiation force results from the absorption or reflection
of the acoustic waves by the encountered medium and
can result in cellular apoptosis [16, 17].
We aim to examine the current literature on the role
of HIFU in pain palliation in advanced pancreatic cancer
and to compare the methodologies used for treatment,
with the goal of providing a comprehensive resource of
comparable data for the design of future studies.
Methods
Article search
A systematic electronic search was performed using the
PubMed Medline database through July 2016. The
electronic system was interrogated with the following
keywords: “HIFU” AND “Pancreatic cancer”, “HIFU” AND
“Pain” AND “Pancreas”, “HIFU” AND “Pain” AND
“Pancreatic Cancer”, “HIFU” AND “Palliation” AND
“Pancreas”,” HIFU” AND “Palliation” AND “Pancreatic
Cancer”. All variants of HIFU/high intensity focused ultra-
sound, pancreatic/pancreas, cancer/carcinoma, palliation/
palliative were searched. Because some of the research
published in this area was not written in English, it does
not appear in PubMed; therefore, a manual search of the
bibliographies of selected studies and reviews was
completed to supplement the electronic search.
The following exclusion criteria were applied: I) Re-
views II) Studies not including pancreas III) Preclinical
studies IV) Pain assessment not reported V) Reported
imaging appearance or histology other than pancreatic
adenocarcinoma VI) No primary pancreatic tumor VII)
Studies with ≤ 2 patients VIII) Papers analyzing more
than one type of malignancy in which data specific for
pancreatic cancer related pain was not reported. Full-
text articles were screened by SD, CM and PG. Transla-
tion of articles written in Chinese was provided by JHH.
The flow of selection is described using the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) model [19]. (Fig. 1)
Statistical analysis
A meta-analysis of 23 studies on the therapeutic effect
of HIFU on pancreatic cancer, defined as the proportion
of patients having no or reduced pain post-procedure,
was carried out. A logit-transformed random-effects
model using the inverse variance method was used, with
the DerSimonian-Laird estimator for τ2, and Cochran’s
Q test for heterogeneity among studies. The I2 was
calculated to assess the percentage of the total variability
in the different effect size estimates that can be attributed
to heterogeneity among the true effects (substantial het-
erogeneity if I2 > 50%). A rank correlation test of funnel
Fig. 1 PRISMA Flowchart. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses
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40 32 0.80 N/A N/A None None
Gu, 2004
[21]
N/A 38 36 0.95 N/A N/A N/A N/A
Li, 2004
[22]
Pain Scale 10 9 0.90 N/A N/A Skin burn II (1) None
Wu, 2005
[32]
Drug Needs 8 8 1.00 N/A N/A None None
Xie, 2008
[56]











28 22 0.79 N/A N/A None None
Orsi, 2010
[57]




Pain Scale 40 35 0.88 N/A N/A None None
Sung,
2011 [35]








Mild abdominal pain (16), Transient pancreatitis
(7), Transient fever (3), Severe abdominal pain
with vomiting (2)
Pancreaticoduodenal
fistula (2),Skin burn II





3 3 1.00 N/A N/A None None
Li, 2012
[59]




Skin burn I (3) None
Gao, 2013
[60]
Pain Scale 39 31 0.79 N/A N/A None None
Anzidei,
2014 [24]
Pain Scale 6 6 1.00 7 +/- 1 3 +/- 1 None None
Sofuni,
2014 [61]
Pain Scale 21 16 0.76 N/A N/A Mild pancreatitis (1) Pseudocyst formation (2) None
Marinova,
2016a [23]
Pain Scale 13 10 0.77 N/A N/A Mild to severe abdominal pain (7), Skin burn II
(1), Induration subcutaneous fat tissue (1), Local

















15 12 0.80 N/A N/A Transient subcutaneous edema (9), Skin burn II








23 15 0.65 N/A N/A None None
Pain Scale 20 15 0.75 None
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plot asymmetry was done to assess possible publication
bias. All statistical analyses were done with R 3.1.2 and
version 4.4.0 of the “meta” package (r-project.org).
Results
Search results and characteristics of the included studies
The primary electronic search identified 82 articles.
Following the application of the exclusion criteria and
the unavailability of one paper [20], 17 studies were
selected. Six further studies were added from the manual
research, five of which were translated from the Chinese
language. A total of 23 studies were included in the stat-
istical analysis. Studies were published between 2001
and 2016. Sixteen studies were from China, three from
Italy, three from Germany, and one from Japan.
The demographic and clinical data are listed in Table 1.
The studies include a total number of 865 patients; 729
had pancreatic cancer, of which 639 underwent HIFU
treatment. The population enrolled ranges from 3
patients in the smallest series, up to 61 in the largest
study. All 729 pancreatic cancers included were deemed
unresectable. Three out of 20 papers were not limited to
pancreatic cancer but also included other abdominal or
pelvic malignancies. In 4 papers HIFU was combined
with chemotherapy (2 with Gemcitabine, 1 with S-1 and
in 1 is not specified), in 1 with radiotherapy and in the
other 16 papers focused ultrasound was variably associ-
ated with prior chemotherapy and/or radiotherapy. In
two clinical studies the patients were divided into two
groups, comparing chemotherapy alone to a combin-
ation treatment including HIFU. MRI guidance was per-
formed only in one study; the others used B-mode
ultrasound.
Clinical outcome
Among 639 patients treated with HIFU, 567 complained
of pancreatic pain before the treatment. After HIFU, 459
patients experienced a partial or complete pain relief
(Table 2). The random effects estimate of proportion of
patients with pain reduction was 0.81 (95% CI: 0.76–86)
(Fig. 2). Based on this result, we can conclude that 81%
of patients may expect to have pain relief after HIFU
treatment, notwithstanding that we have to take into
consideration the variability among the studies. There-
fore, the lower boundary of 76% is a more conservative,
and probably more valid, estimate of the true value.
The I2 of the included studies was 40% (95% CI: 1–64%).
This result indicates that multiple effect sizes are possibly










Mild severe abdominal pain (13), Cutaneous/
subcutaneous edema (11), Subcutaneous tissue
induration (1), Skin burn IIa (1), Increase in lipase
(3)
Fig. 2 Random Effects Model – Studies included in the analysis. Proportion of patients with pain reduction
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present, most probably because of the considerable variabil-
ity in patients, treatments and other parameters in the pub-
lications. In fact, the Q test p-value was 0.026, confirming a
significant heterogeneity among studies, as shown in Fig. 2.
The funnel plot (Fig. 3) suggests a possible publication bias,
with small less-successful studies missing, but the test of
asymmetry was not statistically significant (p = 0.054).
Pain evaluation was heterogeneous among the studies,
and the follow up periods were not consistent, with
different or not specified assessment intervals. Eighteen
studies used a quantitative estimate of the pain, adopting
a numerical scale, VAS (Visual Analog Scale) or NRS
(Numerical Range Scale) ranging from 0 to 10, with ten
defined as the maximum pain experienced and 0 no pain
reported. The associated use of painkillers was variably
included in the definition of pain relief; although most
of the patients reduced or discontinued the use of anal-
gesic medications, it is not possible to quantify this rate
due to heterogeneous reporting of the details of opioid
analgesia in these papers.
The tumor response was not part of the statistical ana-
lysis since there were no uniform criteria, methodology
and timing of evaluation among the studies. The modality
of assessment and the number of patients with a tumor
response after ultrasound ablation are summarized in
Table 3. The most common criteria for the evaluation of a
positive response were: changes in grey scale on US,
RECIST (Response Evaluation Criteria in Solid Tumors)
guidelines, WHO criteria, lack of contrast enhancement,
lack of vascularity and reduction in size. With MRgFUS
the Non Perfused Volume on MRI images was evaluated
using 60% as threshold to define an efficacious treatment.
Excluding two studies that did not report the data, 74% of
the patients treated with HIFU had a positive tumor
response.
The most commonly encountered mild adverse
events following HIFU were mild to severe abdominal
pain (n = 38, 5.9%), followed by edema (n = 26, 4.1%)
and first and second degree skin burns (n = 11, 1.7%).
Only eight cases of severe complications were reported
(1,2%). (Table 2).
HIFU Technique
Preoperatively, a medical history, physical examination
and biochemical laboratory blood tests were collected.
The preparation of the patient differed among the
studies. The most common procedures are reported.
Before HIFU the patient underwent bowel preparation
with 12–24 h fasting. Abdominal skin was prepared
in order to avoid local skin burns with shaving and
cleaning of the area. A pad located between the
transducer and the patient’s abdomen was used to
displace bowel loops from the US beam pathway.
Additional procedures were: laxatives, liquid diet,
traditional Chinese medication [21, 22], and a stom-
ach tube to administer antifoaming agents and bind
air bubbles [23]. If necessary, biliary stenting or a
cholecystojejunostomy was performed to prevent or
relieve the presence of obstructive jaundice.
Most of the studies included used US-guided HIFU de-
vices, either the JC Model (Chongqing HIFU Technology
Co, Ltd., Chongqing, China) or the FEB-BY HIFU system
(Yuande Biomedical Engineering Limited Corporation,
Beijing, China) (Table 1). Both systems use ultrasonog-
raphy to visualize the tumor and to monitor tumor abla-
tion; the main difference between these two is in the
pattern of delivery and intensity of the ultrasound waves.
The JC Model system delivers continuous wave focused
ultrasound with high intensity, in the 5–20 kW/cm2 range,
that allows a unique session treatment but requires
sedation or general anesthesia and hospitalization of the
patient. The FEB-BY system employs pulsed-wave focused
ultrasound with low intensities, less than 3 kW/cm2. This
results in the need for more than one treatment session
per patient (from 4 to 7), but most treatments do not
require sedation or hospitalization (Table 4) [18]. One
study used an MRgFUS device (ExAblate 2100; InSightec,
Haifa, Israel), performing all the procedures on a 3-T MRI
scanner. The frequencies of the system range from 0.95 to
1.35 MHz, and the energy from 100 to 7200 J. The treat-
ment was performed under general anesthesia with con-
trolled respiration to overcome motion artifacts [24].
Overall, procedures were performed under different con-
ditions of analgesia: 8 studies administered general
anesthesia, 3 used sedative analgesia, 1 regional anesthesia
and 3 patients had epidural anesthesia. 6 studies did not
use any anesthetic and 5 papers did not report this
Fig. 3 Funnel plot demonstrating possible but not statistically
significant publication bias in assessment of pain (P > 0.05). -Dashed
diagonal lines indicate 95% CI
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CT or MRI absence of perfusion 64
Zhao, 2010
[45]
CT RECIST 32 2 15 15 5
Orsi, 2010
[57]
PET/CT, CT or MRI focal uptake of FDG, low attenuation at the





CT decreased enhancement 35 0 7 28 5
Sung, 2011
[35]
MRI stack model (unenhanced area) 46
Orgera,
2011 [58]





US, CT hyperechogenicity, and hypovascularity(US), tumor




CT or MRI decrease or disappearance of blood supply in
target region and circular enhancement in tumor
periphery
30 0 5 25 9
Anzidei,
2014 [24]
CT and MRI changes in density and intensity, contrast




CT WHO criteria 26 0 4 22 4
Marinova,
2016a [23]
US lack of contrast enhancement 13
Li YJ, 2016
[34]
MRI, CT, US RECIST 11 0 7 4 5
Li X, 2016
[49]
CT RECIST 16 1 15 N/A N/A
Strunk,
2016 [62]
US, CT, MRI tumor ablation rate (NPV/total volume) 8
Lv, 2016
[48]
CT RECIST 18 0 10 8 0
Marinova,
2016b [36]
CT and MRI tumor volume reduction N/A
FDG flurodeoxyglucose, NPV non perfused volume, CDFI color doppler flow imaging, RECIST response evaluation criteria in solid tumors
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effective treatment depth 3.5–
14.0 cm; practice focused sphere
0.3 × 0.3 × 0.8 cm; effective focused
sphere of 0.6 × 0.6 × 0.6 cm
N/A 1–2 kW pulsed 40 patients received in total
more than 280 HIFU treatments







depth of effective therapy 2–15 cm;
actual focus measurement 0.3 ×
0.3 × 0.8 cm; effective focus of 0.6 ×










effective therapy depth of 2–15 cm;
practice focused sphere of 0.3 ×
0.3 × 0.8 cm; effective focused
sphere 0.6 × 0.6 × 1 cm
N/A 1–2 kW pulsed 8.4 average (range 5–12). Patients
with abdominal and back pain
got abdominal ganglion






12 cm diameter; focal length
13.5 cm; focal region: 9.8 mm along
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N/A continuous 1.5 average (2 patients had 2








effective therapy depth: 17 cm;
focused sphere: 0.3 × 0.3 × 0.8 cm
1 MHz maximum
output power:
600 W in the
study: 200–
300 W






overall aperture 37 cm; focal length
26 cm; -6 dB focal dimensions:
0.8 cm in length, 0.3 cm in diameter







effective therapy depth 2–15 cm;




continuous Gemcitabine on days 1, 8 and 15,
and multiple HIFU sessions on
days 1, 3 and 5. The combined
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13.5 cm; focal region: 8 mm along
beam axis, 1.5 mm in transverse
direction











20 cm diameter; system operated by
using one of several therapeutic
transducers with focusing lengths
that varied from 9 to 16 cm (13.7 cm
focusing length most used in the
study)
0.8 MHz (either 0.8
or 1.6 MHz for each



















aperture of 37 cm; focal distance
25.5 cm; focus has a 6 dB beam
width of 1.6 mm and an axial length
of 1 cm; effective therapy depth 2-
15 cm
1 MHz 400–1000 W
mean: 586 +/-
78.4 W
pulsed 1.2 average (19 patients had 1
session, 6 patients had 2
sessions)
0.85 MHz N/A continuous
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information. MRgFUS was performed in a single treat-
ment session, whereas the USgFUS was often delivered in
several sessions, with the number of sessions varying
based on the device used, general health of the patient
and size of the tumor to be ablated.
Post-operatively, the skin was evaluated for development
of skin burns, and biochemical blood tests were used to
monitor for the development of pancreatitis. Depending
on the study’s design and the authors’ preferences, several
imaging modalities were used immediately after HIFU and
in the post-treatment period to assess ablation and tumor
response.
Discussion
The origin of pain from pancreatic cancer is multifactor-
ial, resulting from tumor infiltration of nerves, tumor
mass compression and inflammatory reaction elicited by
the malignancy [25, 26]. The mechanisms by which
HIFU relieves pain are not completely understood.
Three possibilities have been proposed: 1) thermal dam-
age to the nerves innervating the tumor, 2) fibrosis and
shrinkage of the tumor after ablation, resulting in re-
duced mass effect, and 3) the inactivation of the fibers of
the celiac plexus that normally transmit the pain sensa-
tion centrally [10].
Our study suggests that HIFU is a very effective mean
of relieving pain in patients with pancreatic cancer.
Despite the heterogeneity in the studies published in the
literature, 81% of patients had a partial or total decrease
of pain following the treatment. Case reports published
in the literature, excluded from our analysis because of
their small sample size, are consistent with our findings
on the efficacy and safety of HIFU for pain palliation
[27–31].
Not all papers reported the duration of pain relief. The
longest follow up period was reported by Wu et al., with
no pain progression seen in a up to 17 months, and
Anzidei et al., with pain alleviation persisting at 6 months
[24, 32]. Wang et al. and Li YJ et al. reported a median
pain relief time of 10 weeks and 5.6 months, respectively
[33, 34]. Other studies with short-term follow up
(≤3 months) confirm the relief of pain [23, 35, 36].
The main treatment proposed when opioids fail in pain
control is currently neurolytic celiac plexus blockade
(NCPB). NCPB involves percutaneous or endoscopic injec-
tion of anesthetics and neurolytic substances (Ethanol or
Phenol) along the celiac plexus in order to interrupt noci-
ceptive transmission [25]. The actual efficiency in the re-
duction of pain is variable and, in some studies, it has been
questioned [13, 37]. Although response rates as high as
70–90% were initially reported [12], a subsequent meta-
analysis of five randomized control trial demonstrated only
a 6% reduction in pain scores after neurolytic celiac plexus
blockade [13]. NCPB has also been reported to result in
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reduced opioid use and related side effects [37–39]. How-
ever, Wong et al., in a double blinded randomized control
trial that compare NCPB to a placebo, found no difference
in opiate use or side effects between the two groups [40].
Most of the studies found a short duration of analgesia,
lasting about 3 months [38, 39, 41, 42], with repeated
NCPB demonstrating reduced efficacy (29% in repeated vs
67% after initial block) [42]. Indeed, the most commonly
encountered side effects in NCPB include: local pain
(96%), transient diarrhea (44%) and hypotension (36%)
[12, 41]. More severe adverse events occur in 2% of
patients, including but not limited to: pneumothorax,
shoulder, chest and pleuritic pain. One percent of
these complications are neurological, with occurrence
of paraplegia representing the major concern [12, 41].
Focused ultrasound technology appears to be an
attractive alternative because it is non-invasive, provides
rapid pain relief and has a high safety profile [10], it has
also been used successfully after NCPB has failed [24]. It
offers the potential for a multimodal therapeutic
approach for patients with pancreatic cancer, providing
pain palliation and the possibility of local tumor control
and increased local delivery of chemotherapeutic agents
[15]. Compared with neurolytic celiac plexus blockade,
the rate of adverse effects in our studies was consider-
ably lower. HIFU has a high safety profile, with only
eight cases of severe complications (1.3%) reported in
our analysis. In a study published by Jung et al., the
adverse events after HIFU treatment for hepatic and
pancreatic cancer were listed. Among them, there were
skin redness, edema and pain in the treated region; for
the 35 patients with pancreatic cancer treated with
HIFU, 3rd-degree skin burn (n = 1, 2.9%) and fistula for-
mation between the tumor and the duodenum were
listed as major complications (n = 3, 8.5%) [43]. In our
studies, the most common side effect encountered is
mild to severe abdominal pain, followed by skin burns of
various degree. The abdominal pain is usually self-
limited, with only one case requiring hospitalization.
The most feared adverse event following HIFU is bowel
perforation due to interposition of the intestinal loops
along the ultrasound beam pathway; two cases of pan-
creaticoduodenal fistula (0.3%) occurred among our
patients. Eight patients developed mild or transient pan-
creatitis (1.3%) classified as minor complication, in nine
further patients there was a mild increase of lipase on
blood analysis without any clinical signs of pancreatitis
(1.4%). Unlike chemotherapy, HIFU does not have
systemic side effects that limit dose or number of appli-
cations and in contrast to radiation therapy, it is not a
risk for poor wound healing or secondary malignancies.
In these studies, local tumor control achieved after
HIFU was assessed through different imaging methods.
Among 639 patients who underwent HIFU for
pancreatic cancer, 455 had a positive tumor response ex-
cluding two studies not reporting this data (Table 3).
These studies reveal that tumor response is not always
correlated to pain relief, suggesting that complete abla-
tion is not necessary for pain relief. Xiong et al. observed
pain improvement in 88% of patients who had an object-
ive tumor response but also in 76.2% of patients who did
not [44]. Similarly, Zhao et al. observed pain relief in
88.2% of patients with a tumor response and in 35% of
patients with stable or progressive disease [45]. Tumor
size reduction does not appear to be a sensitive way to
evaluate HIFU efficacy, neither in terms of the effect on
pain relief nor for the evaluation of successful ablation.
Indeed, in the short term, despite the reduction in pain,
the volume of the mass may appear unchanged or
increased due to local edema [46, 47].
Pancreatic adenocarcinoma is relatively hypovascular
and is surrounded by a thick fibrous ring that limits the
penetration and diffusion of chemotherapeutic agents,
accounting in part for the poor responsiveness to
pharmacological treatment. Recent studies have demon-
strated that HIFU may have a synergistic effect with
chemotherapy, boosting the drug concentration in the
tumor and reducing the systemic toxicity. The under-
lying mechanisms proposed are increased permeability
of vascular endothelial cells and enhanced diffusion of
the chemotherapeutic agent under the radiation force
from the ultrasound field [15]. Among the studies
included in our analysis, two compare the combination
treatment of HIFU plus chemotherapy to chemotherapy
alone. Lv et al. conclude that the difference in pain relief
between the two groups was significantly improved in
the HIFU combination group (65.2% vs 31.8%); although
the disease control rate was also higher in the HIFU
group (78.2% vs 59.0%), this was not statistically differ-
ent. Moreover, the combination therapy was associated
with considerably improved survival rates at 6 months
(73.9% vs 40.9%, P < 0.05), but not at 12 months (13.0%
vs 4.5%, P > 0.05) [48]. Li X et al. reported similar results
with a significant better overall survival (10.3 months vs
6.6 months), PFS (Progression Free Survival: 5.1 months
vs 2.3 months), objective tumor response (26.2% vs
8.5%), and remission rate of pain (57% vs 20%) [49].
Good control of pain relief has a significant impact on
the quality of life of the patient, but further studies are
needed to assess the potential that this may have on
survival. Survival benefit following HIFU has been previ-
ously reported in the literature. Vidal et al. observed an
unexpectedly prolonged survival time for patient with
stage III and stage IV pancreatic carcinoma treated with
HIFU and chemotherapy, with the longest survival of
3.4 years. Moreover, the estimate of the survival was sur-
prisingly high, with 33.5% pancreatic cancer patients still
alive at 4.2 years [50]. HIFU was combined with
Dababou et al. Journal of Therapeutic Ultrasound  (2017) 5:9 Page 13 of 16
gemcitabine in this study; considering the absence of a
control arm, it is possible that the improved survival
partially reflects patients that responded well to chemo-
therapy. Most of the studies included in our analysis
have not been designed to assess the survival benefit of
HIFU in the treatment of advanced pancreatic cancer.
The median overall survival is reported in 12 studies; the
range is 7–25 months with a median value of 10 months.
These data are very heterogeneous with no definition of a
starting point nor duration of follow-up. Moreover, some
of the papers report survival after HIFU-only while others
after HIFU combined with other treatments. Clearly,
further research is needed to validate these results.
The main limitation in our study is the lack of random-
ized controlled trials and the considerable heterogeneity
in the data reported by the single papers, which some-
times made comparison of the results not feasible. The
most important differences were in the evaluation of pain,
assessment of tumor response and technique used for the
treatment. It was not possible for us to estimate quantita-
tively the reduction of pain following HIFU, as most of the
papers did not use a numerical scale to assess the differ-
ence at baseline and follow up. Moreover, the timing of
pain evaluation was not consistent, while precise intervals
would allow an estimate of pain relief in the long term. A
considerable heterogeneity was observed in the use of an-
algesic drugs, in terms of need of pain medications after
treatment, opioid or non-opioid use, and eventual doses
required. Some studies defined pain relief considering only
the absolute decrease in pain, while others included the
change in analgesic drugs need. Likewise, the tumor re-
sponse evaluation differed in the criteria, timing and
methodology used to evaluate it. A more consistent follow
up time is necessary to assess longer term results and to
address the potential survival benefit following HIFU.
Uniformity is needed in the inclusion criteria used and in
the description of the characteristics of the tumor treated
(histological type, location, size, stage) in order to make
data more homogeneous and comparable.
Most of the current literature reports experience with
USgFUS, and few reports suggest the feasibility and
safety of MRgFUS. The US guided methodology uses
ultrasound for both the detection and ablation of the
lesion, allowing identification of potential obstructions
in the US beam pathway, such as air. USgFUS has some
limitations: its contrast resolution may not be adequate
to depict accurately the borders of the lesion, it lacks a
real-time temperature monitoring to ensure adequate
ablation, and it is operator dependent. MRgFUS is
promising, because of improved tissue contrast allow-
ing definition of the tumor and surrounding structures
and because of real time MR thermometry, which
allows better targeting and monitoring of the ablated
region [16, 46, 51, 52].
Even though most of the studies were performed with
US guided HIFU, standardization of energy, power and
technical parameters are lacking, and still needed to
obtain the best results at the minimum risk for the
patient. The studies included used two different US
systems; indeed, the biological effect of continuous wave
HIFU can have considerable differences from the pulsed
wave focused ultrasound in terms of biological effects
on the tissue, interaction with other therapeutic regi-
mens and clinical response of the patient. Not all papers
specified if HIFU was applied alone or with concurrent
chemotherapy/radiotherapy. In the future, these data
need to be specified to better discriminate the potential
of HIFU as single therapy and the effects of combination
therapies on tumor response.
Therefore, there is need for uniformly designed studies
in order to determine the data necessary to report in
each trial, in order to objectively evaluate the treatment
results. A clinical registry of the results of HIFU treat-
ment of pancreatic cancer is planned. This will provide
an analytical tool useful to assess the eventual benefit of
HIFU on the overall survival and pain palliation in pan-
creatic cancer, which is still a poorly treated aggressive
tumor bearing a poor prognosis.
Conclusions
Although the literature is heterogeneous, our study sup-
ports that High Intensity Focused Ultrasound is a potent
tool for pain palliation in unresectable pancreatic cancer.
The potential role of HIFU requires further well designed
studies to confirm its efficacy, safety and advantages
compared to other palliative techniques.
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